MX9202243A - Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio. - Google Patents

Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.

Info

Publication number
MX9202243A
MX9202243A MX9202243A MX9202243A MX9202243A MX 9202243 A MX9202243 A MX 9202243A MX 9202243 A MX9202243 A MX 9202243A MX 9202243 A MX9202243 A MX 9202243A MX 9202243 A MX9202243 A MX 9202243A
Authority
MX
Mexico
Prior art keywords
angiotensin
pharmaceutical composition
receptor antagonist
calcium channel
channel blockers
Prior art date
Application number
MX9202243A
Other languages
English (en)
Spanish (es)
Inventor
Pancras Chor Bun Wong
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of MX9202243A publication Critical patent/MX9202243A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX9202243A 1991-05-15 1992-05-14 Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio. MX9202243A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15

Publications (1)

Publication Number Publication Date
MX9202243A true MX9202243A (es) 1992-11-01

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202243A MX9202243A (es) 1991-05-15 1992-05-14 Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.

Country Status (11)

Country Link
EP (1) EP0584250A1 (enExample)
JP (1) JP2930252B2 (enExample)
AU (1) AU664375B2 (enExample)
CA (1) CA2103276A1 (enExample)
CZ (1) CZ281570B6 (enExample)
IE (1) IE921534A1 (enExample)
IL (1) IL101858A (enExample)
MX (1) MX9202243A (enExample)
NZ (1) NZ242724A (enExample)
WO (1) WO1992020342A1 (enExample)
ZA (1) ZA923557B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンii介在性諸疾患の予防または治療剤
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
ES2193233T3 (es) 1995-03-16 2003-11-01 Pfizer Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ剤
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
MXPA05008142A (es) * 2003-01-31 2005-09-30 Sankyo Co Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
DK0565634T3 (da) * 1990-12-14 1999-09-27 Smithkline Beecham Corp Angiotensin-II-receptorblokkersammensætninger

Also Published As

Publication number Publication date
JPH06508128A (ja) 1994-09-14
IL101858A (en) 1996-08-04
WO1992020342A1 (en) 1992-11-26
AU2026992A (en) 1992-12-30
JP2930252B2 (ja) 1999-08-03
CA2103276A1 (en) 1992-11-16
EP0584250A1 (en) 1994-03-02
EP0584250A4 (enExample) 1994-03-30
CZ235193A3 (en) 1994-03-16
CZ281570B6 (cs) 1996-11-13
ZA923557B (en) 1993-11-15
IL101858A0 (en) 1992-12-30
IE921534A1 (en) 1992-11-18
AU664375B2 (en) 1995-11-16
NZ242724A (en) 1994-09-27

Similar Documents

Publication Publication Date Title
MX9202243A (es) Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.
BR9206722A (pt) Antagonista receptores de endotelina
IL99246A0 (en) Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
FI935175L (fi) Tyrosinkinas- HER4-humanreceptor
DK0667148T3 (da) Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen
DK0938318T3 (da) Tablet med kontrolleret frigivelse af alfuzosinchlorhydrat
ATE397459T1 (de) Sofort auflösbare medizinische zusammenstellung
FI941178A7 (fi) 5-HT4-reseptoriantagonisteja
FI922919L (fi) Mild vaordschampo med hoeg skumnivao
ITSV970008V0 (it) Apparecchio ortodontico per l'espansione e la contrazione ortodontica e ortopedica del mascellare superiore.
FI914262A7 (fi) 3-aryyli-4(3H)kinatsolinoni-CCK-antagonisteja ja niiden farmaseuttisiaformulaatioita
DE69429861D1 (de) Endothelin-rezeptor-antagonisten
MA22288A1 (fr) Compositions de shampooings doux
FR2675372B1 (fr) Prothese ossiculaire auto-ajustable de l'oreille moyenne.
FI914855L (fi) Ekstrudoitavan eteeni-hydroksiakrylaatti-sekapolymeerin käyttö
IT1301451B1 (it) Copolimeri del clorotrifluoroetilene
IS4597A (is) Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
FI920190A7 (fi) Päällevalettava valmiste matolääkkeiden antamiseksi
DE69604968D1 (de) Wagenblockierkeil
BR9609914A (pt) Antagonista do receptor de endotelina
EP0914611A4 (en) TRANSACTIVATION OF LEPTIN
AR002996A1 (es) Isoxazolinas mejoradas antagonistas del receptore de fibrinogeno.
IT1283608B1 (it) Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
DE69227940D1 (de) Menschlicher Neurokinin-1-Rezeptor
BR9006118A (pt) Monitor de canal multiplex